logo
Plus   Neg
Share
Email

Crocs CFO Carrie Teffner To Resign; Anne Mehlman Named Successor

While reporting its second-quarter financial results today, Crocs Inc. (CROX) said that Carrie Teffner, Executive Vice President and Chief Financial Officer, has announced her intention to resign from the company effective April 1, 2019 to pursue strategic board and advisory work.

Anne Mehlman has been named Teffner's successor and will assume the Executive Vice President and CFO role effective August 24, 2018.

Upon Mehlman's arrival, and to ensure a seamless transition, Teffner will transition into the role of Executive Vice President Finance and Strategic Projects.

Mehlman brings more than 15 years of global financial and operational experience to her role. She will join Crocs from Zappos.com, Inc., an online shoe retailer owned by Amazon, where she is CFO.

Before joining Zappos.com, Inc. in 2016, Mehlman was a member of the Crocs management team for over five years, most recently as Vice President Corporate Finance.

Earlier in her career, she served as Division Finance Director at RSC Holdings, Inc., a construction and industrial equipment rental company, acquired by United Rentals, Inc., and as Northeast Regional Controller at Corporate Express, an international B2B seller of office supplies, acquired by Staples, Inc.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT